The Interactive Patient Profiler for AdreView is a simulation tool designed to help educate physicians on the use of AdreView (Iobenguane I 123 Injection) to assess mortality risk in patients with heart failure. The tool demonstrates the types of patients where the use of AdreView can provide further information to assist physicians in identifying patients who may have a lower one- and two-year mortality risk, among groups of patients with similar profiles based on other clinical information.

As the 2014 Annual Meeting for the Society of Nuclear Medicine and Molecular Imaging (SNMMI) came to a close this year, Molecular Imaging sat down with Barry A. Siegel, MD, professor of radiology and medicine and chief of the nuclear medicine division at Washington University School of Medicine here in St. Louis. Siegel was honored this year with the most prestigious award presented during the meeting: the Benedict Cassen Prize.

General discontent followed a one-time, exponential price hike from Jubilant DraxImage starting April 1 for the company’s exclusive MAA kit for the preparation of technetium-99m albumin, a lung perfusion agent. An industry forum on challenges in the radiopharmaceutical realm presented during the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2014 Annual Meeting in St. Louis featured a panel of speakers, including vice president of sales, marketing and business development for JDI, Kevin Brooks, who made a case for the company.

Piramal Imaging released details from research presented at the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), currently underway at St. Louis Convention Center in St. Louis, Mo.

It is widely publicized that amyloid in the brain may not be the best agent for gauging progression and severity of Alzheimer’s disease. Tau imaging seems to hold greater promise in that arena. What does this mean for amyloid imaging?

Human epidermal growth factor receptor 2 (HER2) biomarkers have been the standard for imaging agents that target hormonally active breast cancers that tend to be very aggressive. Now researchers have developed an alternative and potentially more comprehensive biomarker of disease, HER3, according to a study presented during this week’s Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting, which was held June 7-11 in St. Louis.

An emerging radiotracer homes in on prostate-specific anatomy and finds elusive lesions, according to a study presenting this year at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting.

The combination of late-life depression and beta-amyloid deposition may lead to a quickening of neurodegeneration and progressive Alzheimer’s disease, according to a study presented during the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting, which concludes today.